Anti-obesity medication

Mechanisms of action

Energy intake

• 5-HT2C receptor agonists reduce appetite by working on serotonin receptors in a region of the brain called the hypothalamus. Lorcaserin (Belviq) was FDA approved for weight loss but was withdrawn from the market because a safety clinical trial shows an increased occurrence of cancer.
• Cannabinoid receptor antagonists were developed to treat obesity because researchers noticed that cannabinoid agonists (such as THC, the main pharmacologically active component of cannabis), increased appetite. However, some drugs in this class such as rimonabant were withdrawn or ceased development due to concerns about mental health and suicide. More selective drugs—some are in development that act only in peripheral tissues, not the brain—may be able to achieve this result with fewer adverse effects.
• GLP-1 agonists such as tirzepatide, semaglutide, and liraglutide slow gastric emptying and also have neurologically driven effects on appetite. It is unknown if GLP-1 agonists or dual/triple agonists of GLP-1 and/or the glucagon or GIP receptors act solely by reducing energy intake or if they also increase energy expenditure.
• Setmelanotide is an agonist of the melanocortin 4 receptor and is used in people with certain rare genetic conditions that cause obesity. It is less effective and not approved for general obesity.

Energy expenditure

• Adrenergic agonists that work on the beta-2 adrenergic receptor increase energy expenditure. Although some such as clenbuterol are used without medical approval for weight loss, none have achieved approval for this indication due to cardiac risks. The anti-obesity effects of amphetamines, besides acting on the brain to reduce energy intake, are also mediated by the beta-2 adrenergic receptor. Ephedrine (and related compounds that are also active ingredients in ephedra preparations) exert their effects by acting directly and indirectly as adrenergic agonists.
• The discontinued drug 2,4-dinitrophenol works by increasing energy expenditure by decreasing the efficiency of mitochondria (uncoupling agent).
• Fibroblast growth factor-21 receptor agonists and drugs increasing FGF-21 activity are being investigated for obesity-related diseases; they can increase energy expenditure and several have been tested in humans.
• Thyroid hormones, another early weight loss drug, also raised energy expenditure but ceased to be used for weight loss due to cardiac risks and other adverse effects. Selective thyromimetics that work on the thyroid hormone receptor beta may be able to exert some of the beneficial thermogenic effects of thyroid hormones with fewer adverse effects, but none have received approval as of 2023.

Both

• Amylin analogues can both reduce energy intake and increase expenditure and can usefully be combined with leptin analogues for synergistic effect. The dual amylin and calcitonin receptor agonist cagrilintide, in combination with semaglutide, was more effective than semaglutide alone in promoting weight loss in clinical trials.
• Glucagon receptor agonists both reduce energy intake and increase energy expenditure in humans. They can cause hyperglycemia so it is recommended to combine them with a hypoglycemic drug, such as a GLP-1 or GIP receptor agonist.

Other mechanisms

• Bimagrumab, an experimental drug, works by inhibiting the action of myostatin, which limits the size of skeletal muscle. The drug has shown the ability to increase lean mass simultaneously to decreasing fat mass in obese humans, which is beneficial because it preserves or increases energy expenditure while reducing risks associated with excess fat.
• Orlistat (Xenical) and cetilistat are lipase inhibitors that reduce intestinal fat absorption by inhibiting pancreatic lipase, an enzyme that breaks down triglycerides in the intestine. Without this enzyme, triglycerides from the diet are prevented from being hydrolyzed into absorbable free fatty acids and are excreted undigested. Frequent oily bowel movements steatorrhea is a possible side effect of using orlistat. Originally available only by prescription, it was approved by the FDA for over-the-counter sale in February 2007.
• SGLT2 inhibitors cause the loss of 60–100 g glucose in the urine each day and are associated with a modest, sustained weight loss of 1.5-2 kg in people with type 2 diabetes. The weight loss is less than expected due to compensatory increases in energy intake, but is additive when combined with GLP-1 receptor agonists.

History

The first described attempts at producing weight loss are those of Soranus of Ephesus, a Greek physician, in the second century AD. He prescribed elixirs of laxatives and purgatives, as well as heat, massage, and exercise. This remained the mainstay of treatment for well over a thousand years. It was not until the 1920s and 1930s that new treatments began to appear. Based on its effectiveness for hypothyroidism, thyroid hormone became a popular treatment for obesity in euthyroid people. It had a modest effect but produced the symptoms of hyperthyroidism as a side effect, such as palpitations and difficulty sleeping. 2,4-Dinitrophenol (DNP) was introduced in 1933; this worked by uncoupling the biological process of oxidative phosphorylation in mitochondria, causing them to produce heat instead of ATP. Overdose caused fatal hyperthermia and DNP also caused cataracts in some users. After the passage of the Food, Drug, and Cosmetic Act in 1938, the FDA banned DNP for human consumption.

Amphetamines (marketed as Benzedrine) became popular for weight loss during the late 1930s. They worked primarily by suppressing appetite, and had other beneficial effects such as increased alertness. Use of amphetamines increased over the subsequent decades, including Obetrol and culminating in the "rainbow diet pill" regime. This was a combination of multiple pills, all thought to help with weight loss, taken throughout the day. Typical regimens included stimulants, such as amphetamines, as well as thyroid hormone, diuretics, digitalis, laxatives, and often a barbiturate to suppress the side effects of the stimulants. In 1967/1968 a number of deaths attributed to diet pills triggered a Senate investigation and the gradual implementation of greater restrictions on the market. Evidence mounted that the combination could cause valvular heart disease in up to 30 percent of those who had taken it, leading to withdrawal of fen-phen and dexfenfluramine from the market in September 1997.

In the early 2020s, GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) or tirzepatide (Zepbound) became popular for weight loss because they are more effective than earlier drugs, causing a shortage for patients prescribed these medications for type 2 diabetes, their original indication. After the FDA approved semaglutide and tirzepatide for chronic weight management, GLP-1 medications became available through various virtual weight loss programs. GLP-1 receptor agonists are associated with reduced riks of cardiovascular events (such as heart attack and stroke) in adults with obesity.

Patient population

The United States Food and Drug Administration and the European Medicines Agency have approved weight loss medications for adults with either a body-mass index (BMI) of at least 30, or a body-mass index of at least 27 with at least one weight-related comorbidity. This patient population is considered to have sufficiently high baseline health risks to justify the use of anti-obesity medication.

The American Academy of Pediatrics had not previously supported the use of weight loss medication in adolescents but issued new guidelines in 2023, which recommend considering the use of weight loss medication in some overweight children aged 12 or older. The European Medicines Agency has approved semaglutide for children aged 12 or older who have a BMI in the 95 percentile for their age and a weight of at least 60 kg.

Medication

US FDA approved

The US Food and Drug Administration (FDA) approves anti-obesity medications as an adjunctive therapy to diet and exercise for people for whom lifestyle changes do not result in sufficient weight loss. In the United States, semaglutide (Wegovy) is approved by the FDA for chronic weight management. The FDA guidelines say that a therapy may be approved if it results in weight loss that is statistically significant greater than placebo and generally at least five percent of body weight over six months that comes predominantly from fat mass. Some other prescription weight loss medications are stimulants, which are recommended only for short-term use, and thus are of limited usefulness for patients who may need to reduce weight over months or years. As of 2022, there is no pathway for approval for drugs that reduce fat mass without 5 percent overall weight loss, even if they significantly improve metabolic health; neither is there one for drugs that help patients maintain weight loss although this can be more challenging than losing weight.

As of 2022, no medication has been discovered that would equal the effectiveness of bariatric surgery for long-term weight loss and improved health outcomes.

Withdrawn

Never approved or not currently approved

Safety and side effects

Some anti-obesity medications can have severe, even lethal side effects, fen-phen being a famous example. Fen-phen was reported through the FDA to cause abnormal echocardiograms, heart valve problems, and rare valvular diseases. Out of 25 anti-obesity medications withdrawn from the market between 1964 and 2009, 23 acted by altering the functions of chemical neurotransmitters in the brain. The most common side effects of these drugs that led to withdrawals were mental disturbances, cardiac side effects, and drug abuse or drug dependence. Deaths were associated with seven products. Ephedra was removed from the US market in 2004 over concerns that it raises blood pressure and could lead to strokes and death.

Weight regain

Weight regain is common upon discontinuation of weight loss medications, and long-term therapy may sometimes be required for sustained weight loss.

After stopping treatment with GLP-1 agonists such as semaglutide, liraglutide and tirzepatide, people regain on average more than half (50–70%) of the lost weight within 1 year.

References

References

1. (September 2021). "Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?". Journal of Obesity & Metabolic Syndrome.
2. (May 2021). "Targeting Energy Expenditure—Drugs for Obesity Treatment". Pharmaceuticals.
3. {{NICE. 43. Obesity: The prevention, identification, assessment and management of overweight and obesity in adults and children. 2006
4. (28 November 2023). "Obesity Management in Adults: A Review". JAMA.
5. Constantino, Annika Kim. (2026-01-10). "2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market".
6. (2015). "Lorcaserin Hcl for the treatment of obesity". Expert Opinion on Pharmacotherapy.
7. (19 February 2019). "FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market".
8. (March 2021). "Cannabinoid Receptors in Metabolic Regulation and Diabetes". Physiology.
9. (2019). "Overcoming the psychiatric side effects of the cannabinoid CB1 receptor antagonists: current approaches for therapeutics development". Current Topics in Medicinal Chemistry.
10. (September 2014). "Effects of GLP-1 on appetite and weight". Reviews in Endocrine & Metabolic Disorders.
11. (December 2020). "Comprehensive Review of Current and Upcoming Anti-Obesity Drugs". Diabetes & Metabolism Journal.
12. (July 2023). "Adverse events of clenbuterol among athletes: a systematic review of case reports and case series". International Journal of Legal Medicine.
13. (July 2020). "Unravelling novel weight loss mechanisms". Nature Reviews Endocrinology.
14. (July 2018). "Centrally Acting Drugs for Obesity: Past, Present, andFuture". Drugs.
15. (December 2021). "In search of an ideal drug for safer treatment of obesity: The false promise of pseudoephedrine". Reviews in Endocrine and Metabolic Disorders.
16. (May 2017). "FGF21-receptor agonists: an emerging therapeutic class for obesity-related diseases". Hormone Molecular Biology and Clinical Investigation.
17. (October 2023). "A narrative review of approved and emerging anti-obesity medications". Saudi Pharmaceutical Journal.
18. (April 2022). "Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss". Obesity.
19. (November 2023). "Pharmacological modulation of adaptive thermogenesis: new clues for obesity management?". Journal of Endocrinological Investigation.
20. (December 2016). "Gut hormones such as amylin and GLP-1 in the control of eating and energy expenditure". International Journal of Obesity Supplements.
21. (August 2016). "Amylin-mediated control of glycemia, energy balance, and cognition". Physiology & Behavior.
22. (July 2023). "Coadministration of the long-acting amylin analog cagrilintide plus semaglutide ( CagriSema ), resulted in significantly greater weight loss, along with improved measures of glucose control, in a short phase 2 trial of patients with type 2 diabetes". Diabetes, Obesity and Metabolism Now.
23. (April 2022). "GLP-1 – Incretin and pleiotropic hormone with pharmacotherapy potential. Increasing secretion of endogenous GLP-1 for diabetes and obesity therapy". Current Opinion in Pharmacology.
24. (April 2022). "Is Glucagon Receptor Activation the Thermogenic Solution for Treating Obesity?". Frontiers in Endocrinology.
25. (July 2023). "The molecular pharmacology of glucagon agonists in diabetes and obesity". Peptides.
26. (August 2008). "Cetilistat (ATL-962), a novel pancreatic lipase inhibitor, ameliorates body weight gain and improves lipid profiles in rats". Hormone and Metabolic Research.
27. (8 July 2015). "Orlistat (marketed as Alli and Xenical) Information".
28. (2019). "Emerging Role of SGLT-2 Inhibitors for the Treatment of Obesity". Drugs.
29. (November 1974). "Dinitrophenol and bioenergetics: an historical perspective". Molecular and Cellular Biochemistry.
30. (2010). "Perspectives on Twentieth-century Pharmaceuticals". Peter Lang.
31. (September 2012). "The return of rainbow diet pills". American Journal of Public Health.
32. (October 2005). "Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on 'fen–phen'". Expert Opinion on Drug Metabolism & Toxicology.
33. Pool, Robert. (2001). "Fat: Fighting the Obesity Epidemic". Oxford University Press.
34. (March 2023). "GLP-1/GIP analogs: potential impact in the landscape of obesity pharmacotherapy". Expert Opinion on Pharmacotherapy.
35. "GLP-1 receptor agonists: Breaking down the hype and demand". American Pharmacists Association.
36. "FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014".
37. "FDA Approves New Medication for Chronic Weight Management".
38. (February 2007). "Guidance for Industry Developing Products for Weight Management".
39. (11 November 2021). "Wegovy".
40. (9 January 2023). "A major medical group updated its guidance for treating childhood obesity. Here's what it says.". NBC News.
41. (2023-02-01). "Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity". Pediatrics.
42. "European Medicines Agency recommends weight loss drug Wegovy for teenagers 12 and up". Diabetes.
43. (12 September 2023). "Latest Obesity Drug Not Cost-Effective for Adolescents".
44. (21 June 2021). "FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014".
45. "Obesity Medication: Gastrointestinal Agents, Other, CNS Stimulants, Anorexiants, Glucagon-like Peptide-1 Agonists, Antidepressants, dopamine reuptake inhibitors; opioid antagonists".
46. (March 2022). "Anti-obesity drug discovery: advances and challenges". Nature Reviews Drug Discovery.
47. (March 2021). "Once-Weekly Semaglutide in Adults with Overweight or Obesity". The New England Journal of Medicine.
48. (13 June 2013). "Qsiva".
49. (March 2013). "Phentermine/topiramate for the treatment of obesity". The Annals of Pharmacotherapy.
50. (June 2021). "Efficacy and Safety of Phentermine/Topiramate in Adults with Overweight or Obesity: A Systematic Review and Meta-Analysis". Obesity.
51. (17 September 2018). "Mysimba EPAR".
52. (March 2021). "Clinical Impact of Liraglutide as a Treatment of Obesity". Clinical Pharmacology: Advances and Applications.
53. (November 2022). "AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity.". Gastroenterology.
54. (February 2019). "A Randomized, Double-Blind, Placebo-Controlled Study of Gelesis100: A Novel Nonsystemic Oral Hydrogel for Weight Loss". Obesity.
55. (January 2007). "Drug treatments for obesity: orlistat, sibutramine, and rimonabant". Lancet.
56. (October 2006). "Effects on Weight Reduction and Safety of Short-Term Phentermine Administration in Korean Obese People". Yonsei Medical Journal.
57. (8 November 2023). "FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems".
58. (2023-10-15). "Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial". Nature Medicine.
59. (June 2019). "Lorcaserin treatment decreases body weight and improves cardiometabolic risk factors of obese adults: A 6-month-long, randomized, placebo-controlled, double-blind clinical trial.". Diabetes, Obesity & Metabolism.
60. "Meridia (sibutramine): Market Withdrawal Due to Risk of Serious Cardiovascular Events".
61. (23 October 2012). "Recalls and safety alerts". Government of Canada.
62. (September 2018). "Body Weight Reduction Associated with the Sibutramine Treatment: Overall Results of the PRIMAVERA Primary Health Care Trial". Obesity Facts.
63. (February 2011). "An overview of the metabolic effects of rimonabant in randomized controlled trials: potential for other cannabinoid 1 receptor blockers in obesity: The metabolic effects of rimonabant". Journal of Clinical Pharmacy and Therapeutics.
64. (July 1998). "The fen-phen finale: a study of weight loss and valvular heart disease". Obesity Research.
65. (November 1996). "Dexfenfluramine". Drugs.
66. (August 1935). "Dinitrophenol in the Treatment of Obesity: Final Report". Journal of the American Medical Association.
67. (8 December 2021). "Role of OTC Asthma Medications in the Community Pharmacy".
68. (November 2021). "Effects of Ephedrine-Containing Products on Weight Loss and Lipid Profiles: A Systematic Review and Meta-Analysis of Randomized Controlled Trials". Pharmaceuticals.
69. (2015). "Nutritional Supplements in Sports and Exercise". Springer International Publishing.
70. (July 1992). "Effectiveness of phenylpropanolamine in the management of moderate obesity". International Journal of Obesity and Related Metabolic Disorders: Journal of the International Association for the Study of Obesity.
71. (June 2023). "Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial". The New England Journal of Medicine.
72. (January 2012). "Short-Term Exenatide Treatment Leads to Significant Weight Loss in a Subset of Obese Women Without Diabetes". Diabetes Care.
73. (January 2010). "Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical)". Obesity (Silver Spring).
74. (June 2010). "Tesofensine, a Novel Triple Monoamine Reuptake Inhibitor, Induces Appetite Suppression by Indirect Stimulation of α1 Adrenoceptor and Dopamine D1 Receptor Pathways in the Diet-Induced Obese Rat". Neuropsychopharmacology.
75. (January 2013). "Effectiveness of metformin on weight loss in non-diabetic individuals with obesity". Experimental and Clinical Endocrinology & Diabetes.
76. (December 2021). "Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial". The Lancet.
77. (2025). "Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity". New England Journal of Medicine.
78. "FDA Announces Withdrawal Fenfluramine and Dexfenfluramine (Fen-Phen)". U.S. [[Food and Drug Administration]] (FDA).
79. (2016). "Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review". BMC Medicine.
80. Kolata, Gina. (2007). "Rethinking thin: The new science of weight loss – and the myths and realities of dieting". Picador.
81. (2025-10-02). "A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults". Nature Medicine.
82. (2025-05-28). "Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption: A Narrative Review of Randomized Studies". Journal of Clinical Medicine.